HDAC6 and plasma cell myeloma: Treatment of multiple myeloma (MM) cells with a panel of FDA-approved and investigational HDAC6 inhibitors dramatically increased MHC-I antigen presentation and significantly enhanced the antimyeloma activity of healthy and patient-derived autologous T-cells.